TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02207049

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Snacking
Description: Snacks will be provided to preschoolers, either as part of total caloric needs or above total caloric needs

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Snacking
Description: Snacks will be provided to preschoolers, either as part of total caloric needs or above total caloric needs

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Snacking
Description: Caloric needs will be provided to preschoolers within three meals
Study: NCT02274935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Balance and gait exercise twice a week for an hour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Balance and gait exercise twice a week for an hour
Study: NCT04209634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pozelimab
Description: Single loading intravenous (IV) dose on day 1, then fixed doses sub-cutaneous (SC) (based on body weight) QW (±2 days) over the treatment period.
Study: NCT05252013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Bean Hull Bread
Description: The bean hull bread will deliver 21.96 g of fibre. Volunteers will consume a roll of bean hull bread (155g/portion) served with 25g of raspberry jam.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Experimental: Plain Bread
Description: The control bread will deliver 4.53 g of fibre. Volunteers will consume a roll of plain bread (122g/portion) served with 25g of raspberry jam.
Study: NCT02269553

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMJ(TM) NextGeneration
Description: The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Hard TMJD Splint
Description: The occlusal splint to be used in this study will be a hard, full-arch splint with at least one occlusal contact on each tooth of the opposing arch.
Study: NCT02353702

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sniff test
Description: Evaluation of diaphragmatic function by sniff test after continuous parietal infusion of ropivacaine or placebo

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sniff test
Description: Evaluation of diaphragmatic function by sniff test after continuous parietal infusion of ropivacaine or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusion of Ropivacaine during 48 hours
Description: 20 ml Bolus (7,5 mg/ml) then continuous administration of 10 ml per hour (2 mg/ml) during 48 hours of Ropivacaine.~20 ml Bolus (NaCl 0.9 %) then continuous administration of 10 ml per hour, during 48 hours of NaCl 0.9 %.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous parietal infusion with parietal catheter
Description: Continuous parietal infiltration of Ropivacaine or placebo

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous parietal infusion with parietal catheter
Description: Continuous parietal infiltration of Ropivacaine or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Infusion of placebo during 48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Study: NCT00281099

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICD (Implantable Cardioverter Defibrillator)
Description: VVI 40 vs. MVP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICD (Implantable Cardioverter Defibrillator)
Description: VVI 40 vs. MVP
Study: NCT03216343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiauranib
Description: CS2164
Study: NCT01016119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folrex
Description: Folrex cream, in the early rehabilitations in the upper extremity, before daily rehabilitation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
Study: NCT02553551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: During the period of hospitalization, Intake of vitamin C 3000 mg per day via oral route until the day of discharge.~After discharge, no additional vitamin C pill was given.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the period of hospitalization, Intake of gelatinous capsule three times per day via oral route until the day of discharge.~After discharge, no additional capsule was given.
Study: NCT01996696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg PO TID x 30-36 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo TID x 30-36 months
Study: NCT02644213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protocol of using CAREN and MOTEK systems
Description: The subjects will perform randomly 3 experimental days (at least weak between one to another):~* simulated road march using a virtual reality environment without additional load~* simulated road march using a virtual reality environment which combines cognitive load during the road march. Cognitive tasks for example: navigation, identification and remembering cars/aircraft.~* without physical or cognitive load (without march, waiting between performance evaluations) as control.
Study: NCT02248441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily ischemic conditioning treatment
Description: RIC stimulus will be conducted as 4 x 5 minutes upper arm ischemia achieved by inflation of a blood pressure cuff to 200 mmHg and 5 minutes reperfusion between inflations. The procedure will be performed using the AutoRICTM (CellAegis Devices Inc., Toronto, Ontario, Canada).
Study: NCT06660641

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TaurolockTMHep100
Description: 1.35% taurolidine containing catheter losk solution
Study: NCT01489488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (BAY63-2521)
Description: Single oral dose of 2.4 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 16 mL) under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (BAY63-2521)
Description: Single oral dose of 0.3 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 2 mL) under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (BAY63-2521)
Description: Single oral dose of 0.15 mg riociguat as pediatric low-concentration suspension (0.03 mg/mL, i.e. 5 mL) under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (BAY63-2521)
Description: Single oral dose of riociguat immediate release (IR) tablet 1 mg under fasting conditions
Study: NCT01894191

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Air insufflation
Description: Insufflation during colonoscopy including insertion phase

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: water immersion
Description: Water will infused during insertion phase and removed during withdrawal phase of colonoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Water exchange
Description: Water will infused and removed during insertion phase of colonoscopy
Study: NCT01410032

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plate fixation
Description: Reconstruction plate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESIN
Description: ESIN (Elastic Stable Intramedullary Nailing)
Study: NCT03364023

Intervention type: DEVICE
Intervention: Neurothrombectomy
Description: Medtronic Market-Released Neurothrombectomy Device
Study: NCT03340701

Intervention type: DRUG
Group type: OTHER
Intervention: vaginal progesterone suppository
Description: 200mg vaginal suppository micronized progesterone
Study: NCT06259266

Intervention type: OTHER
Group type: OTHER
Intervention: Anti-reflux valve for dialysis catheter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-reflux valve for dialysis catheter
Study: NCT03920033

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Salvage radiation therapy
Description: Salvage radiation therapy for biochemical recurrence

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Salvage radiation therapy
Description: Salvage radiation therapy for biochemical recurrence
Study: NCT01651195

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT00963196

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acid
Description: 2400mg daily of fish oil containing 1440mg combined EPA and DHA for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acid
Description: 2400mg daily of fish oil containing 1440mg combined EPA and DHA for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acid
Description: 2400mg daily of fish oil containing 1440mg combined EPA and DHA for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bovine gelatin capsules
Description: Bovine gelatin capsules that appear similar to active drug acting as placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bovine gelatin capsules
Description: Bovine gelatin capsules that appear similar to active drug acting as placebo.
Study: NCT02058550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone-based intervention
Description: Receive reminder phone call
Study: NCT01816659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: 500 mg by mouth once daily, beginning the day after colonoscopy for one week, and then escalation to 1000 mg/day. The duration of the trial will be from the preoperative endoscopy till the surgery, and should be not less than 10 days and not more than 30 days.
Study: NCT01275430

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sherlock 3CG
Description: Sherlock 3CG is indicated for central venous catheter guidance and positioning during catheter placement. The Sherlock 3CG provides real time catheter tip location information through the use of passive magnet and cardiac electrical signal detection.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blind Placement
Description: PICCs will be placed blindly, without the use of any tip location/positioning device.
Study: NCT00963196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bovine gelatin capsules
Description: Bovine gelatin capsules that appear similar to active drug acting as placebo.
Study: NCT02114814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes self-management program for Hispanics and their families
Description: The intervention group received an 8-weekly culturally tailored diabetes self-management and family support education program delivered in Spanish

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General health educational program for Hispanics and their families
Description: The attention control group received 8-weekly education program on general health information
Study: NCT01140243

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LCPUFA
Description: premature infant formula supplemented with LCPUFA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LCPUFA
Description: premature infant formula supplemented with LCPUFA
Study: NCT02546804

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HOT SALT WATER
Description: 25ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POTASSIUM PERMANGANATE
Description: 10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CHLORHEXIDINE
Description: 10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
Study: NCT04254471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL3810
Description: 5mgQD, 7.5mgQD, 10mgQD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL3810
Description: 5mgQD, 7.5mgQD, 10mgQD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin + etoposide
Description: Carboplatin and etoposide are background treatment.
Study: NCT03351140

Intervention type: OTHER
Intervention: PROMIS Physical Function Items
Description: PROMIS Physical Function Items is a set of self-report measurement tools. The latest version of PROMIS Physical Function Items contains 165 items for self-assessment. PROMIS Physical Function Cancer Item Bank contains a subset of 45 items relevant to cancer subjects. Subjects will complete half of the PROMIS Physical Function Items during their enrollment visit and the other half of items prior to their interview.

Intervention type: OTHER
Intervention: PROMIS Physical Function Items
Description: PROMIS Physical Function Items is a set of self-report measurement tools. The latest version of PROMIS Physical Function Items contains 165 items for self-assessment. PROMIS Physical Function Cancer Item Bank contains a subset of 45 items relevant to cancer subjects. Subjects will complete half of the PROMIS Physical Function Items during their enrollment visit and the other half of items prior to their interview.
Study: NCT04254471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin + etoposide
Description: Carboplatin and etoposide are background treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin + etoposide
Description: Carboplatin and etoposide are background treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01437722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% SPL7013 Gel
Description: vaginal gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% SPL7013 Gel
Description: vaginal gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: vaginal gel
Study: NCT02787668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted diet
Description: Participants will be randomized (20 per group) to the carbohydrate restricted diet (i.e., CHO \<10%; fat \>65%, protein 25%) or a low fat diet (CHO 55%; fat 20%; protein 25%) for 8 weeks. Individual counseling with the study physician and registered dietitian (RD) will be provided at baseline for initial assessment and diet instruction. Participants will meet with a RD for an individual counselling session at week 2, 4, and 6 of the diet intervention to ensure adherence to the diet prescription. Participants will be encouraged to keep track of dietary intake by using electronic food diaries (weeks 1-8) to review with the RD during individual counseling at week 2, week 4 and week 6.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control, low-fat diet
Description: Individual counseling with the study physician and registered dietitian (RD) will be provided at baseline for initial assessment and diet instruction. Participants will meet with a RD for an individual counselling session at week 2, 4, and 6 of the diet intervention to ensure adherence to the diet prescription. Participants will be encouraged to keep track of dietary intake by using electronic food diaries (weeks 1-8) to review with the RD during individual counseling at week 2, week 4 and week 6.
Study: NCT03351140

Intervention type: OTHER
Intervention: PROMIS Physical Function Items
Description: PROMIS Physical Function Items is a set of self-report measurement tools. The latest version of PROMIS Physical Function Items contains 165 items for self-assessment. PROMIS Physical Function Cancer Item Bank contains a subset of 45 items relevant to cancer subjects. Subjects will complete half of the PROMIS Physical Function Items during their enrollment visit and the other half of items prior to their interview.
Study: NCT01789723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fusilev
Description: Fusilev will be administered by IV push (3-5 minutes) at a dose of 5 mg/m2. Fusilev administration, QID or BID will start 24 ± 3 hours after Folotyn administration depending on the dose cohort.
Study: NCT04388709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Lambda-1A
Description: Peginterferon lambda-1a (Lambda) 180mcg subcutaneous injection once
Study: NCT01204853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxentan
Description: sitaxentan sodium 100 mg
Study: NCT02222974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIR 561 CL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01213745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attention
Study: NCT01789723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fusilev
Description: Fusilev will be administered by IV push (3-5 minutes) at a dose of 5 mg/m2. Fusilev administration, QID or BID will start 24 ± 3 hours after Folotyn administration depending on the dose cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fusilev
Description: Fusilev will be administered by IV push (3-5 minutes) at a dose of 5 mg/m2. Fusilev administration, QID or BID will start 24 ± 3 hours after Folotyn administration depending on the dose cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fusilev
Description: Fusilev will be administered by IV push (3-5 minutes) at a dose of 5 mg/m2. Fusilev administration, QID or BID will start 24 ± 3 hours after Folotyn administration depending on the dose cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fusilev
Description: Fusilev will be administered by IV push (3-5 minutes) at a dose of 5 mg/m2. Fusilev administration, QID or BID will start 24 ± 3 hours after Folotyn administration depending on the dose cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folotyn
Description: A cycle of Folotyn treatment is 7 weeks, 6 weeks of treatment followed by 1 week of rest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folotyn
Description: A cycle of Folotyn treatment is 7 weeks, 6 weeks of treatment followed by 1 week of rest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folotyn
Description: A cycle of Folotyn treatment is 7 weeks, 6 weeks of treatment followed by 1 week of rest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folotyn
Description: A cycle of Folotyn treatment is 7 weeks, 6 weeks of treatment followed by 1 week of rest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folotyn
Description: A cycle of Folotyn treatment is 7 weeks, 6 weeks of treatment followed by 1 week of rest.
Study: NCT02863783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS with Fiducial
Description: EUS will be used to place fiducial into pancreas tumor at time of biopsy
Study: NCT01421511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA
Description: * TR-701 FA 200 mg once daily in 250 mL sterile saline for injection as a 60 minute IV infusion~* TR-701 FA Tablets, 200 mg, orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: * Linezolid 600 mg IV Injection twice daily in 300 mL sterile saline for injection as a 60 minute IV infusion~* Linezolid Tablets, 600 mg, orally every 12 hours
Study: NCT01213745

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study: NCT02943928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laryngoscope and chest CT image
Description: First,the operator calculate the distance between the carina and the glottis by CT image and make s marker on the double lumen endotracheal tube. Then the operator when inserted into the double lumen tube under the visualof laryngoscope until see marker just at the glottis
Study: NCT02563444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound fusion guiding system - TUS A-500 (Aplio 500)
Study: NCT01384760

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: During the first 4 months, subjects will come for a counseling session weekly and then monthly for the following months. During each counseling session (15 to 20 minutes), the registered dietitian will review the seven-day food diaries and offer recommendations for controlling caloric intake. A varied balanced diet with an emphasis on fruit and vegetables, and low-fat and low calorific products in appropriate portions were encouraged. The registered dietitian will also review the daily activity log sheet to check the exercise adherence and progression set by exercise instructor. Subjects will be encouraged to do 30 minutes aerobic exercise two to three times a week.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Simple lifestyle advice
Description: Subjects in control group will receive simple lifestyle advice from a clinician at baseline and month 6. This will be a brief discussion about the general health risk associated with OSA and importance of balanced diet. Subjects are encouraged to perform regular 30-minute exercise 2 to 3 times per week. This is to resemble routine clinical practice.
Study: NCT02635945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-680

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo